| Insider Overview :: Lorus Therapeutics Inc. (T:LOR) | [?] |
| Business Focus: Biotechnology & Medical Research | |
|
|
| |
| Latest 10 SEDI filings (by transaction date) for LOR within the last 6 months | [?] |
| | |
| As of 11:59pm ET May 23rd, 2013 | |||||||
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | # or value acquired or disposed of | Price |
| No SEDI filings within the past 6 months or filings data currently unavailable. Sign up for an account or login above to see all SEDI filings within the past 6 months. | |||||||
| Latest 10 SEDI filings (by filing date) for LOR within the last 6 months | [?] |
| | |
| As of 11:59pm ET May 23rd, 2013 | |||||||
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | # or value acquired or disposed of | Price |
| No SEDI filings within the past 6 months or filings data currently unavailable. Sign up for an account or login above to see all SEDI filings within the past 6 months. | |||||||
| Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider. |
| No Markers (TSX Insider Summaries) for LOR on May 23, 2013 | [?] |
| To view marker data for the past week, sign up for an account or log in above. To view more history, sign up for an account at inkresearch.com |
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Key People | ||
| Jim A. Wright Chairman of the Board | Aiping H. Young President, Chief Executive Officer, Director | Elizabeth Williams Acting Chief Financial Officer, Director - Finance | Yoon Lee Vice President - Research |
| Company Contact | |
| Address: | 2 Meridian Road TORONTO ON M9W 4Z7 |
| Tel: | 1-514-9393989 |
| Website: | www.lorusthera.com |
| IR: | www.lorusthera.com/investors/index.php |
| Business Overview |
| Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem). |
| Competitors with Recent Insider Filings |
| QLT (T:QLT) |
| EnWave (V:ENW) |
| iCo Therapeutics (V:ICO) |
|